迈克生物收盘上涨1.43%，滚动市盈率243.63倍，总市值73.93亿元

Group 1 - The core viewpoint of the news is that Maike Biological's stock performance and financial metrics indicate a significant decline in revenue and profit, alongside a high price-to-earnings (PE) ratio compared to industry averages [1][2][3] Group 2 - As of May 16, Maike Biological's stock closed at 12.07 yuan, with a PE ratio of 243.63, marking a new low in 28 days and a total market capitalization of 7.393 billion yuan [1] - The average PE ratio in the medical device industry is 49.40, with a median of 36.13, placing Maike Biological at the 117th position in the industry ranking [1][3] - For the first quarter of 2025, the company reported a revenue of 510 million yuan, a year-on-year decrease of 17.22%, and a net profit of 23.98 million yuan, down 80.09% year-on-year, with a gross margin of 56.76% [2]